Nectero Medical Recognized as a 2024 AZBio Fast Lane Award Winner
September 24, 2024 08:00 ET
|
Nectero Medical
TEMPE, Ariz., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, announced today that it received a...
Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program
September 24, 2024 07:30 ET
|
Cytokinetics, Incorporated
Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is November 4th, 2024 SOUTH SAN...
Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
September 24, 2024 07:30 ET
|
Ocugen
MALVERN, Pa., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
September 24, 2024 07:00 ET
|
Can-Fite BioPharma Ltd.
The agreement has been signed upon successful conclusion of a clinical study in dogs with osteoarthritis RAMAT GAN, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE...
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
September 24, 2024 06:00 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Life Sciences Week 2024: Advancing Innovation, Investment, and Collaboration in Alberta’s Life Sciences Sector
September 23, 2024 13:10 ET
|
Applied Pharmaceutical Innovation (API)
Life Sciences Week, Alberta’s flagship event for showcasing the life sciences sector returns from September 23 to 27, 2024.
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
September 23, 2024 08:00 ET
|
Assembly Biosciences, Inc.
– ABI-5366 was well-tolerated, with a favorable safety profile observed with exposure of up to 70 days – – Half-life of approximately 20 days supports once-weekly or once-monthly oral dosing; both...
Human Augmentation Market - Forecasts from 2024 to 2029: Advances in AI, Biotechnology, Nanotechnology, Robotics, and Materials Science Fueling Developments
September 23, 2024 07:26 ET
|
Research and Markets
Dublin, Sept. 23, 2024 (GLOBE NEWSWIRE) -- The "Human Augmentation Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's offering.The human augmentation market is...
Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting
September 19, 2024 16:00 ET
|
Cytokinetics, Incorporated
Analyses of Effects of Aficamten on Key Clinical Outcomes from SEQUOIA-HCM to be Featured in Late Breaking Clinical Trial Presentation at HFSA SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE...
Keck Graduate Institute Awarded $750,000 Grant from the Department of Energy to Study Low-Level Radiation Effects
September 19, 2024 14:34 ET
|
Keck Graduate Institute
Claremont, CA, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Keck Graduate Institute (KGI), a member of The Claremont Colleges, has been awarded a significant grant from the Department of Energy to investigate...